352 related articles for article (PubMed ID: 8295327)
1. [Clinical study of GM-CSF in patients with aplastic anemia and myelodysplastic syndrome. (CSF39-300 Study Group)].
Kitamura K; Asano S; Mizoguchi H; Takaku F
Rinsho Ketsueki; 1993 Dec; 34(12):1540-9. PubMed ID: 8295327
[TBL] [Abstract][Full Text] [Related]
2. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
3. [Effect of subcutaneous administration of interleukin-1 beta on blood platelet count and serum GM-CSF in patients with myelodysplastic syndrome and aplastic anemia].
Furuya H; Ishibashi R; Wakayama T; Ohguni S; Notsu K; Takagi C; Kato Y
Rinsho Ketsueki; 1992 Sep; 33(9):1172-7. PubMed ID: 1433938
[TBL] [Abstract][Full Text] [Related]
4. GM-CSF clinical trials: pediatric aplastic anemia and Fanconi's anemia.
Lopez KD; Guinan EC
Pediatr Nurs; 1995; 21(4):345-9. PubMed ID: 7644282
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in bone marrow failure.
Antin JH; Smith BR; Holmes W; David RN; Rosenthal S
Behring Inst Mitt; 1988 Aug; (83):149-53. PubMed ID: 3071331
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of aplastic anemia with KRN8601 (rhG-CSF)].
Kojima S; Matsuyama T; Miyazaki T; Sakurada K; Shike S; Okino E; Akabane T; Nakahata T; Okuni M; Mugishima H
Rinsho Ketsueki; 1990 Jul; 31(7):929-36. PubMed ID: 1699006
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of myelopoiesis in patients with aplastic anemia by recombinant human granulocyte-macrophage colony-stimulating factor.
Vadhan-Raj S; Buescher S; Broxmeyer HE; LeMaistre A; Lepe-Zuniga JL; Ventura G; Jeha S; Horwitz LJ; Trujillo JM; Gillis S
N Engl J Med; 1988 Dec; 319(25):1628-34. PubMed ID: 3059191
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome.
Antin JH; Smith BR; Holmes W; Rosenthal DS
Blood; 1988 Aug; 72(2):705-13. PubMed ID: 3042046
[TBL] [Abstract][Full Text] [Related]
9. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
Wu HH; Talpaz M; Champlin RE; Pilat SR; Kurzrock R
Cancer; 2003 Dec; 98(11):2410-9. PubMed ID: 14635076
[TBL] [Abstract][Full Text] [Related]
10. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
Vadhan-Raj S; Keating M; LeMaistre A; Hittelman WN; McCredie K; Trujillo JM; Broxmeyer HE; Henney C; Gutterman JU
N Engl J Med; 1987 Dec; 317(25):1545-52. PubMed ID: 3500414
[TBL] [Abstract][Full Text] [Related]
11. [Clinical study of rhG-CSF (KRN8601) in patients with myelodysplastic syndrome].
Toyama K; Ohyashiki J; Takaku F; Kobayashi Y; Miyazono K; Miura Y; Sakamoto S; Mizoguchi H; Hoshino S; Urabe A
Rinsho Ketsueki; 1990 Jul; 31(7):937-45. PubMed ID: 1699007
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of recombinant human granulocyte-macrophage colony-stimulating factor in myelodysplastic syndrome and aplastic anemia.
Takahashi M; Yoshida Y; Kaku K; Masaoka T; Moriyama Y; Nakanishi S; Kaneko T; Shibata A; Miwa S
Acta Haematol; 1993; 89(4):189-94. PubMed ID: 8212999
[TBL] [Abstract][Full Text] [Related]
13. Plasma lactoferrin content in neutropenic patients: effects of treatment with recombinant granulocyte-macrophage colony-stimulating factor.
Bezwoda WR; Dajee D
Mol Biother; 1992 Jun; 4(2):103-6. PubMed ID: 1515094
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of G-CSFR and GM-CSFR expressions on CD34+ cells in patients with aplastic anemia and myelodysplastic syndrome.
Xu H; Li A; Yu Y; Li J; Liu X; Wang X; Wang X; Xu G
Int J Lab Hematol; 2009 Dec; 31(6):597-602. PubMed ID: 18637807
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes.
Stasi R; Pagano A; Terzoli E; Amadori S
Br J Haematol; 1999 Apr; 105(1):141-8. PubMed ID: 10233377
[TBL] [Abstract][Full Text] [Related]
16. Use of recombinant GM-CSF following allogeneic BMTs for aplastic anemia.
Chap L; Schiller G; Nimer SD
Bone Marrow Transplant; 1993 Aug; 12(2):173-5. PubMed ID: 8401368
[TBL] [Abstract][Full Text] [Related]
17. [Emergency therapy with granulocyte-macrophage colony-stimulating factor (GM-CSF)].
Gratwohl A; Dazzi H; Tichelli A; Stebler C; Wernli M; Thomssen C; Kim I; Dieterle A; Obrist R; Stern A
Schweiz Med Wochenschr; 1991 Mar; 121(12):413-7. PubMed ID: 2028244
[TBL] [Abstract][Full Text] [Related]
18. The effect of granulocyte-macrophage colony stimulating factor on paroxysmal nocturnal hemoglobinuria: a case report.
Webb DI; Bundtzen JL
Alaska Med; 1993; 35(3):216-7, 224. PubMed ID: 8109693
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 3 and interleukin 3/GM-CSF combination therapy--clinical implications.
Ganser A; Ottmann OG; Hoelzer D
Stem Cells; 1993 Nov; 11(6):465-73. PubMed ID: 8111306
[No Abstract] [Full Text] [Related]
20. Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia.
Kurzrock R; Talpaz M; Gutterman JU
Am J Med; 1992 Jul; 93(1):41-8. PubMed ID: 1626572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
